Top-News

Pivotal Therapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A1J0EA
ISIN: CA72582E1043
US-Symbol: PVTTF
Typ: Aktie

Pivotal Therapeutics News

01.04.15 - PR Newswire
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid ...
17.12.14 - PR Newswire
VASCAZEN® POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA
VASCAZEN® POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA PR Newswire
08.10.14 - PR Newswire
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor PR Newswire
07.10.14 - PR Newswire
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN® and Statin Therapy
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN® and Statin Therapy PR Newswire
10.09.14 - PR Newswire
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients PR Newswire
03.09.14 - PR Newswire
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014 PR Newswire
27.08.14 - PR Newswire
Pivotal Therapeutics Announces Second Quarter Financial Results
Pivotal Therapeutics Announces Second Quarter Financial Results PR Newswire
19.08.14 - PR Newswire
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation PR Newswire
19.08.14 - PR Newswire
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation PR Newswire
06.08.14 - PR Newswire
Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China PR Newswire
11.06.14 - PR Newswire
Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations
Pivotal Therapeutics engages Kilmer Lucas for cross-​border investor relations PR Newswire
30.05.14 - PR Newswire
Pivotal Therapeutics Announces First Quarter Financial Results
Pivotal Therapeutics Announces First Quarter Financial Results PR Newswire
14.05.14 - PR Newswire
Pivotal Therapeutics announces changes to the Board of Directors
Pivotal Therapeutics announces changes to the Board of Directors PR Newswire
13.05.14 - PR Newswire
Pivotal Therapeutics Engages Brandkarma LLC.
Pivotal Therapeutics Engages Brandkarma LLC. PR Newswire
07.05.14 - PR Newswire
Pivotal Therapeutics announces issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA:DHA formulation
Pivotal Therapeutics announces issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA:DHA formulation PR Newswire
06.05.14 - PR Newswire
Pivotal Therapeutics presented two posters at American Heart Association's ATVB 2014 Scientific Sessions
Pivotal Therapeutics presented two posters at American Heart Association's ATVB 2014 Scientific Sessions PR Newswire
02.05.14 - PR Newswire
Pivotal Therapeutics to present at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions
Pivotal Therapeutics to present at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions PR Newswire
02.05.14 - PR Newswire
Pivotal Therapeutics issues correction to 2013 financial results press release
Pivotal Therapeutics issues correction to 2013 financial results press release PR Newswire
02.05.14 - PR Newswire
Pivotal Therapeutics Announces 2013 Financial Results
Pivotal Therapeutics Announces 2013 Financial Results PR Newswire
30.04.14 - PR Newswire
Pivotal Therapeutics announces resignation of directors
Pivotal Therapeutics announces resignation of directors PR Newswire

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »